U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224451) titled 'Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery' on Nov. 03.
Brief Summary: Objective: To identify new central nervous system (CNS) biomarkers to be used for blood-derived liquid biopsy once the blood-brain barrier (BBB), specifically the blood-arachnoid barrier (BAB), has been transiently disrupted by BDF in patients undergoing spine surgery.
Design: Single center (Sheba Medical Center), prospective, controlled. Phase: Feasibility study
Endpoints:
Efficacy The primary endpoint of the study is the elevation in blood concentration of CNS biomarkers following the study proc...